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Accepted 11 June 2013BK virus is a small nonenveloped, double-stranded DNA
virus from the polyomaviridae family. It was originally iso-
lated from a renal transplantation patient with ureteric
stenosis [1]. BK virus is widespread in the general pop-
ulation, with 90% of the population positive by adulthood [2].
Primary infection causes mild respiratory illness and then
the virus enters a latent phase, particularly in the urogenital
tract (kidneys, urinary bladder, prostate) and lymphoid
tissues (tonsils). Periodically, BK virus reactivates and sheds
into the urine of 5% to 10% of healthy hosts without symp-
toms [3]. However, BK virus reactivation is common in
immune-compromised patients, and it causes a variety of
clinical manifestations, including asymptomatic hematuria,
hemorrhagic cystitis, ureteral stenosis, and interstitial
nephritis [4-6]. Hemorrhagic cystitis (HC) is the most prev-
alent complication among recipients of allogeneic hemato-
poietic stem cell transplantation (HSCT), with an incidence
ranging from 10% to 25%, and it is associated with signiﬁcant
morbidity and mortality [7]. In 1986, Arthur et al. [8] pub-
lished a series of 53 patients showing that HC occurred
4 times more frequently in patients who excreted BK virus
than in those who did not. It is now generally believed that
BK virus infection during HSCT is due to reactivation of latent
virus, although new or reinfection has also been postulated.
Many studies later identiﬁed a quantitative association
between BK virus and late HC, and the studies have noted
that BK viruria preceded or coincided with the onset of
disease [4,8]. However, 40% to 50% of HSCT patients with
persistent BK viruria remained free of HC, indicating that
other factors, such as conditioning regimen intensity, acute
GVHD, severity of immune suppression, unrelated donor, and
presence of anti-BK virus IgG before transplantation, con-
tributed to the development of HC [4,5].
In this issue of Biology of Bone Marrow Transplantation,
Laskin et al. [9] study the correlation between BK PCR and HC
in a previously completed prospective cohort of 88 children
(ages, 1.8 to 15.2 years) who received HSCT at single trans-
plantation center. The study collected plasma weekly from
day 0 until day þ100. Plasma BK PCR with at least 1
measurement between days 0 to 14, 15 to 85, and 100  4
after HSCT established 4 cut-off values for BK PCR as follows:
0; 1 to 9999; 10,000 to 99,9999; and 100,000 PCR copies/
mL. The BK PCR in urine was measured only in symptomaticFinancial disclosure: See Acknowledgments on page 1138.
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17 of 88 patients (19%) developed grade 2 HC, according to
Bedi criteria [10]. Among patients with HC, 6 of 17 (35%) had
no detected BK by PCR in their plasmawhereas 11 of 17 (65%)
had positive BK PCR in plasma, with peak value for 53% in the
range of 1 to 9999 copies/mL and peak value for 12% was
100,000 copies/mL. Cox regression models with time-
varying covariates to assess the association between
different BK viremia cutoffs and the development of HC
showed that subjects with a peak plasma BK viral load of 1 to
9999 copies/mL had an adjusted hazard ratio of 4.2 (95%
conﬁdence interval [CI], 1.3 to 13.7), and patients with peak
BK viremia>100,000 copies/mL had an adjusted hazard ratio
of 116.8 (95% CI, 12 to 1136) for development of HC. Factors
that increase risk of HC, in univariate analyses, were age
>7 years and antithymocyte globulin. Graft-versus-host
disease prophylaxis, maximum grade of graft-versus-host
disease, engraftment, and ﬂuoroquinolones did not have
any statistical signiﬁcance. Interestingly, patients with HHV-
6 viremia were at signiﬁcantly higher risk for developing HC,
with a hazard ratio of 7.6 (95% CI, 2.6 to 22.2; P < .01). After
multivariate analysis, BK viremia at a cut-off level of at least 1
to 9999, age, and HHV-6 remained independently signiﬁcant.
The ﬁnding of an HHV-6 viremia association with HC could
be due to the degree of immune suppression and, thus,
supports the role of virus-speciﬁc immunity playing a major
role in BK viremia and late onset HC, instead of immune
reconstitution as part of 3-stage pathophysiology, as sug-
gested by Leung et al. [11]. The degree of immune suppres-
sion could explain why HC is more common after HSCT
compared with after renal transplantation.
Previous studies have found conﬂicting results in regards
to correlation between BK PCR in plasma or urine and inci-
dence of HC. The study by Erard et al. [12] concluded that BK
PCR >10,000 copies/mL has 63% sensitivity and 95% speci-
ﬁcity for diagnosis of HC. However, this observation conﬂicts
with results reported by Gaziev et al. [13], who suggested
that peak BK viruria >100,000 and not BK viremia was
associated with increased risk of HC. Another study by Leung
et al. found that 3-log increase in BK urine PCR copies/mL
was associated with risk of HC [11]. These conﬂicting results
could be due to different population and geographic areas, as
BK virus has 4 different genotypes, I, II, III, and IV, based on
the PV1 gene. These genotypes have different distributions,
geographically and demographically, and because hospitals
use their own PCR assays, some genotypes could be missed.
Even with contradicting recommendations, BK PCR detects
BV virus that, in either plasma or urine, is highly associated
with HC .
This study by Laskin et al. provides the largest cohort of
pediatric patients who received allogeneic HSCT in which
plasma samples were collected prospectively. It conﬁrms the
ﬁndings by Cesaro et al. that BK plasma viral load levelsTransplantation.
R.K. Avery / Biol Blood Marrow Transplant 19 (2013) 1137e11391138>1000 copies/mL causes increased risk of HC [14]. Interest-
ingly Cesaro’s study showed BK viruria occurred at a median
of 18 days (range, 2 to 30), before overt HC, whereas BK
viremia preceded HC by a median of 17 days (range, 0 to 23),
which provides an opportunity for HC prevention.
In conclusion, the study of Laskin et al. demonstrates
a very strong association between BK viremia and risk of HC
in pediatric recipients of HSCT. BK PCR in plasma is a sensi-
tive method to monitor for BK reactivation, and it could be
used in clinical trials to evaluate preemptive treatment for BK
with the primary endpoint of decreasing HC incidence,
similar to the prevention and preemptive guidelines used in
CMV-reactivation management. The ultimate goal of
decreased HC will lead to decreased morbidity and improved
outcomes. This goal also underscores the need for effective
speciﬁc prophylaxis and treatment for BK-associated HC in
our HSCT population. Finally, in light of this study, a larger
multicenter trial is needed with the aim of comparing BK
plasma PCR and BK urine PCR with a universal assay that
detects all 4 genotypes of BK virus.
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described virus (only known since 2001), although studies
of stored blood samples suggest it has been present in
the community going back at least to 1958 [1]. It is a para-
myxovirus, related to respiratory syncytial virus (RSV),
and accounts for between 2% and 7% of community respi-
ratory viral illnesses. As with other community respiratory
viruses, symptoms are frequently nonspeciﬁc at the outset
and include cough, nasal congestion, sore throat, andfever. However, progression to lower respiratory tract
infection can occur. Case series have suggested a high
mortality associated with this infection in transplant
recipients; a report by Englund et al. [2] documented the
association between hMP, respiratory failure, and a septic
shock-like presentation, with death from acute respiratory
failure occurring in 4 of 5 hematopoietic stem cell trans-
plantation (HSCT) recipients. However, despite such reports,
hMP remains an under-recognized cause of infection in
immunocompromised patients.
In this issue an article by Renaud et al. entitled “Mortality
rates of human metapneumovirus and respiratory syncytial
virus lower respiratory tract infections in hematopoietic
stem cell transplant recipients” [3] represents the latest of
many valuable contributions by the group at Fred Hutch-
inson Cancer Research Center to our understanding of
infections after HSCT. Previous work by this group has
elucidated the epidemiology of many different infections
(viral, fungal, bacterial) in this high-risk patient population.
This group’s prior work on respiratory viruses has estab-
lished risk factors and outcomes for these infections and has
